BR112023019407A2 - Composições farmacêuticas compreendendo zolmitriptano - Google Patents

Composições farmacêuticas compreendendo zolmitriptano

Info

Publication number
BR112023019407A2
BR112023019407A2 BR112023019407A BR112023019407A BR112023019407A2 BR 112023019407 A2 BR112023019407 A2 BR 112023019407A2 BR 112023019407 A BR112023019407 A BR 112023019407A BR 112023019407 A BR112023019407 A BR 112023019407A BR 112023019407 A2 BR112023019407 A2 BR 112023019407A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
zolmitriptane
zolmitriptan
treating
dementia
Prior art date
Application number
BR112023019407A
Other languages
English (en)
Inventor
James Lillie
Michael Wood
Original Assignee
Maplight Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maplight Therapeutics Inc filed Critical Maplight Therapeutics Inc
Publication of BR112023019407A2 publication Critical patent/BR112023019407A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições farmacêuticas compreendendo zolmitriptano. são aqui fornecidas composições orais compreendendo zolmitriptano e métodos de uso das mesmas, por exemplo, para o tratamento dos sintomas do transtorno do espectro autista e para o tratamento da agressão em pacientes com demência.
BR112023019407A 2021-03-25 2022-03-24 Composições farmacêuticas compreendendo zolmitriptano BR112023019407A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163165938P 2021-03-25 2021-03-25
US202263306377P 2022-02-03 2022-02-03
PCT/US2022/021738 WO2022204399A1 (en) 2021-03-25 2022-03-24 Pharmaceutical compositions comprising zolmitriptan

Publications (1)

Publication Number Publication Date
BR112023019407A2 true BR112023019407A2 (pt) 2023-11-28

Family

ID=83397893

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019407A BR112023019407A2 (pt) 2021-03-25 2022-03-24 Composições farmacêuticas compreendendo zolmitriptano

Country Status (10)

Country Link
US (1) US20240189240A1 (pt)
EP (1) EP4313037A1 (pt)
JP (1) JP2024512069A (pt)
KR (1) KR20240004330A (pt)
AU (1) AU2022246101A1 (pt)
BR (1) BR112023019407A2 (pt)
CA (1) CA3213383A1 (pt)
IL (1) IL307194A (pt)
MX (1) MX2023011240A (pt)
WO (1) WO2022204399A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117017983B (zh) * 2023-10-09 2023-12-22 中山大学 曲普坦类药物在制备抗感染药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124126B2 (en) * 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
KR20160117596A (ko) * 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
CA3204599A1 (en) * 2015-02-25 2016-09-01 The Regents Of The University Of California 5ht agonists for treating disorders
CA3158781A1 (en) * 2019-10-23 2021-04-29 Michael Wood Methods of treating the symptoms of autism spectrum disorder

Also Published As

Publication number Publication date
WO2022204399A1 (en) 2022-09-29
IL307194A (en) 2023-11-01
JP2024512069A (ja) 2024-03-18
US20240189240A1 (en) 2024-06-13
MX2023011240A (es) 2024-01-12
EP4313037A1 (en) 2024-02-07
KR20240004330A (ko) 2024-01-11
AU2022246101A1 (en) 2023-10-12
CA3213383A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
BR112022017393A2 (pt) Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
ECSP077315A (es) Proteínas de fusión de dominio de unión
BR112013000027A2 (pt) tratamento de distúrbios cognitivos
ATE433980T1 (de) Gyraseinhibitoren und deren verwendungen
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
BR112022004397A2 (pt) Composições para tratamento bucal que compreendem beta ácidos de lúpulo e aminoácidos
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112023006024A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
ZA202110111B (en) Methods and compositions for treating liver disorders
BR112022015380A2 (pt) Composições e métodos para edição de gene de calicreína (klkb1)
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
BR112023019407A2 (pt) Composições farmacêuticas compreendendo zolmitriptano
BR112022010633A2 (pt) Composto de fórmula, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer de tireoide e invenção
BR112018004207A2 (pt) biomarcadores e métodos de tratamento de câncer
BR112022006476A2 (pt) Oligonucleotídeos com análogos de nucleosídeos
BR112018014762A2 (pt) método de tratamento da doença de alzheimer (da) precoce
BR112018017233A2 (pt) uso de i. butyriciproducens e/ou e. hallii, e, composição
BR112021020424A2 (pt) Compostos e métodos para tratamento de distúrbios inflamatórios
BR112023018906A2 (pt) Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica